CHICAGO, IL, May 30, 2025 — Lucence will present new data on the clinical utility of combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in a single liquid biopsy assay at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 30–June 3, 2025 in Chicago.
Powered by Lucence’s proprietary amplicon-based NGS technology, AmpliMark®, the combined ctDNA + ctRNA assay demonstrates enhanced mutation and fusion detection across cancer types—supporting more informed treatment decisions and earlier intervention.
“This combined ctDNA and ctRNA approach enables a broader genomic view from a single blood draw,” said Dr. Min-Han Tan, CEO and Medical Director of Lucence. “These new studies show how we can improve molecular profiling even in cases where ctDNA alone may fall short.”
The two studies being presented are:
🔬 Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC)
This prospective multicenter study demonstrates how the combined assay improves detection of clinically actionable mutations and fusions in patients with metastatic NSCLC, supporting more comprehensive therapy selection.
🔬 Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay
This pan-cancer analysis shows the added value of ctRNA in identifying gene fusions and other variants not captured by ctDNA alone, enabling broader and deeper molecular profiling across multiple tumor types.
Lucence’s ASCO 2025 presentations mark a significant step forward in the evolution of liquid biopsy testing—providing oncologists with more complete information to personalize treatment, especially in advanced cancers.